A nasal vaccine that could finally curb Covid infections is one step closer to a reality after promising early trial results.
The inhaled vaccine, made by researchers in Georgia, successfully reduced the risk of symptomatic Covid infections by 86 percent for three months in people who received it as a booster - almost double the protection the mRNA boosters provide.
Once inhaled, little bits of the parainfluenza virus replicate inside the nasal cavity to trigger an immune response without actually sickening the person Nasal vaccines such as the one currently in development at Georgia-based startup Blue Lake Biotechnology Inc. concentrate the immune protection in the upper airways, positioning powerful antibodies right on the frontlines.
They plan to expand the sample size and will continue recruiting subjects through December.
‘We are excited and encouraged with this result, and through our affiliate, CyanVac LLC, we have submitted a protocol to FDA for a randomized controlled phase 2 trial in which we look forward to more fully evaluating the immunogenicity of the vaccine and to better understanding its protective efficacy.’
The finished product is still a ways off and this is the type of next generation Covid vaccines that public health officials have said are urgently needed in the event that a new variant that is able to circumvent vaccine protection arises.
No comments:
Post a Comment